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Determination of 6-benzylthioinosine in mouse and human plasma by liquid
chromatography–tandem mass spectrometry
Lan Li , Yan Xu , David N. Wald , William Tse
Introduction
6-Benzylthioinosine (6BT) is an adenosine analogue (Fig. 1) and
was originally used in the property studies of adenosine amino-
hydrolase [1]. In the later 1990s, 6BT was found to be potentially
useful in the treatment of toxoplasmosis [2,3] caused by Toxo-
plasma gondii, an intracellular parasite that infects humans and
many other warm-blooded animals [4,5]. Recently, 6BT was iden-
tiﬁed as a promising differentiation-inducing agent for leukemic
cells as less toxic and more efﬁcacious treatment for acute myeloid
leukemia (AML) [6].
According to statistics by American Society of Clinical Oncol-
ogy in 2008, AML is the most common form of acute leukemia
in the United States and is most often observed in elderly pop-
ulation over age 65 [7,8]. The molecular pathogenesis of AML is
generally accepted as a combination of differentiation arrest and
the uncontrolled proliferation of the myeloblasts [9]. The stan-
dard chemotherapyagents suchas adriamycin and cytarabinework
through nonselectively killing highly proliferative cells leading to
signiﬁcant toxicities [8]. Although up to 75% of the patients can
achieve complete remission (CR), the prognosis of the patients
remains poor leading to an average 5-year survival rate as low
as 21% [7]. In contrast to the traditional chemotherapeutics that
are used for the majority of AML patients, the treatment of acute
promyelocytic leukemia (APL, a rare subtype of AML), utilizes a
differentiation-inducing agent, all-trans retinoic acid (ATRA), that
increases the 5-year disease free survival rate of the patients to 74%
through inducing the terminal differentiation of the myeloblasts
[10]. ATRA can be effectively used in combination with low dose
chemotherapeutic agentswithout signiﬁcant toxicity [11]. This dif-
ferentiation approach is especially desirable for elderly patients
who are often not able to tolerate the toxicities of the traditional
chemotherapeutics.
Since ATRA is only useful for AML patients exhibiting the
rare APL subtype, to search for efﬁcacious differentiation-inducing
agents for the treatment of other AML subtypes, Wald et al. [6]
carried out a cell-based compound-library screen. 6BT has been
identiﬁed as a promising differentiation-inducing agent that not
only displays high differentiation-inducing activity to myeloid
leukemia cell lines (i.e., HL-60 and OCI-AML3) and primary cells
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Fig. 1. The chemical structures of 6BT and the internal standard.
of AML patients, but also induces cell death to a subset of AML
cell lines (i.e., HNT34 and MV4-11). Furthermore, 6BT exhibits very
low toxicity to non-malignant cells (i.e., ﬁbroblasts, normal bone
marrow, andendothelial cells). Inmouse xenograft studies, 6BT sig-
niﬁcantly decreased the tumor (HL-60) size and prevented tumor
(HL-60 andMV4-11) formation inpretreatedmice. Flowcytometric
analysis of the dissected tumors showed a 129% increase of CD11b
(a mature myeloid marker) in 6BT treated tumors in comparison to
the untreated ones [6].
The preclinical studies of 6BT for the treatment of AML and
toxoplasmosis demonstrated its high potential to be an investiga-
tional new drug and warrants further therapeutic development.
Therefore, a quantitative analytical method for 6BT is needed for
pharmacological and toxicological studies. Nevertheless, a recent
search by SciFinder® Scholar revealed that there is no analytical
method available to date for quantiﬁcation of 6BT in biological
matrices. Only a qualitative LC–UV method for 6BT and its ana-
logues was reported by Rais et al. [12], which was not validated for
quantitative measurement of 6BT and did not have the sensitivity
and speciﬁcity required for pharmacokinetic study of 6BT.
Given the above considerations, we have developed a novel
LC–MS/MS method for the direct quantiﬁcation of 6BT in both
mouse and human plasma using 2-amino-6-benzylthioinosine
(2A6BT) (Fig. 1) as the internal standard (IS). A liquid–liquid extrac-
tion procedure was developed for plasma sample preparation, and
analytes were separated by YMC ODS-AQ® column using 0.1%
formic acid, 45% acetonitrile and 54.9% deionized water (v/v/v) as
mobile phase. The eluates from the chromatographic column were
detected by tandem mass spectrometer at the positive ionization
mode (ESI+-MS/MS). The method developed ﬁlls the gap of lack-
ing analytical method for quantitative measurement of 6BT, which
has been validated in both mouse and human plasma according to
the US Food and Drug Administration (FDA) guidelines [13], and
applied to a preliminary pharmacokinetic study of 6BT in mice.
Experimental
Chemicals and solutions
6BT and 2A6BT (IS) were kindly provided by the Developmental
Therapeutics Program of the National Cancer Institute (Bethesda,
MD, USA). Dimethylsulfoxide (DMSO), HPLC-grade of acetonitrile
and ethyl acetate were purchased from Sigma–Aldrich (St. Louis,
MO, USA). Formic acid was from Acros (Morris Plains, NJ, USA).
Deionized water was obtained from the Barnstead NANOpure®
water puriﬁcation system (Thermo Scientiﬁc, Waltham, MA, USA).
Pooledblankmouseplasmawaspurchased fromEquitech-Bio (Ker-
rville, TX, USA). Pooled blank human plasma was from Haemtech,
Inc. (Essex Junction,VT,USA). Isoﬂuranewaspurchased fromBaxter
Healthcare Corporation (Deerﬁeld, IL, USA).
6BT and IS stock solutions were prepared and kept as follows:
each compound was weighted out accurately by an analytical bal-
ance and dissolved into an appropriate amount of acetonitrile to a
concentration of 1.00mg/mL; then, each stock solution was pipet-
ted separately into 1.5-mL microcentrifuge tubes at 100L/tube
for 6BT and 25.0L/tube for IS. The microcentrifuge tubes con-
taining either 6BT (100g/tube) or IS (25.0g/tube) stock solution
were dried by vacuum evaporation in a DNA120 SpeedVac® (Ther-
moSavant, Hollbrook, NY, USA) at 25 ◦C for 10min, and kept at
−20 ◦Cuntil use.Whenused, 1.00mLofdeioinizedwaterwasadded
to each tube to make 6BT and IS working solutions at 100 and
25.0g/mL, respectively. The working solutions of 6BT and IS were
freshly prepared daily.
Themobile phase for chromatographic separationwas prepared
by mixing 0.1% formic acid, 45.0% acetonitrile and 54.9% deionized
water (v/v/v).
Instrumentation
The LC–MS/MS system consisted of an Agilent (Santa Clara,
CA, USA) 1100 HPLC and a Micromass (Manchester, UK) Quattro
II triple quadrupole mass spectrometer. The HPLC unit consisted
of two binary pumps, a degasser, an autosampler, an inline ﬁlter
(0.5mpore) (UpchurchScientiﬁc,OakHarbor,WA,USA), aWaters
(Milford, MA, USA) YMC-AQ® column (2.0mm×50mm, 5m par-
ticle size with 120Å pore size), a two-position 6-port switching
valve (Alltech, Deerﬁeld, IL, USA), and apost-column splitter (Valco,
Houston, TX, USA). The LC–MS/MS system operation, data acquisi-
tion and processing were done by Micromass MassLynx software
(version 3.3).
For each analysis, 20L of the sample was injected into the
system. Chromatographic separation was carried out by isocratic
elution using the mobile phase at the ﬂow rate of 100L/min.
By programming of the post-column switching valve, the ﬁrst 2-
min column eluate was diverted to the waste and the later eluate
was detected by the triple quadrupole mass spectrometer after a
post-column split (1:3).
The mass spectrometer was operated at the positive-
electrospray-ionization (ESI+) mode. It was tuned by infusion of
a mixture of 6BT (10.0g/mL) and IS (10.0g/mL) in the mobile
phase at a ﬂow rate of 3L/min with a syringe pump (Harvard
Apparatus, SouthNatick,MA,USA). Theoptimized ionization condi-
tionswere as follows: drying gas 300 L/h, nebuliser 15 L/h, capillary
voltage 3.5 kV, HV lens 0.5 kV, cone voltage 25V, skimmer 1.5V, RF
lens 0.2V, ion source temperature 40 ◦C, ion energy 0.3V. Analyte
quantiﬁcation was based on multiple-reaction-monitoring (MRM)
with the conditions set as follows: argon collision gas 2.0–2.5bar,
collision energy 17eV, dwell time0.4 s, inter-scan delay 0.05 s, low-
and high-mass resolution 15 (for both quadrupoles 1 and 3), and
multiplier 650.
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Preparation of standard solutions, plasma calibrators and
controls, and mouse plasma samples
6BT standard solutions (6.00, 18.0, 20.0, 60.0, 180, 200,
600, 1800, 2000, and 3200ng/mL) and IS standard solution
(100ng/mL) were prepared by serial dilution of 6BT working
solution (100g/mL) and ISworking solution (25.0g/mL), respec-
tively.
6BT mouse and human plasma calibrators (3.00, 10.0, 30.0, 100,
300, and 1000ng/mL)were prepared individually bymixing 100L
of pooled blank plasma, 50.0L of 6BT standard solution (at twice
of the calibrator’s concentration) and 50L of IS standard solution
at 100ng/mL.
6BT mouse plasma controls (3.00, 9.00, 90.0, 900, and
1600ng/mL) and 6BT human plasma controls (3.00, 90.0 and
900ng/mL) were prepared individually by mixing 100L of pooled
blank plasma, 50.0L of 6BT standard solution (at twice of the con-
trol’s concentration) and50Lof IS standard solution at 100ng/mL.
Mouse plasma samples of 6BT pharmacokinetic study (see Sec-
tion 2.6) were prepared by mixing 100L of plasma from mice
injected with 6BT, 50.0L of deionized water and 50.0L of IS
standard solution at 100ng/mL.
Liquid–liquid extraction of 6BT from plasma matrices
Plasma calibrators, controls and animal samples prepared as
described in Section 2.3 were extracted using the following proto-
col: 1mL of ethyl acetate was added into a 1.5mL microcentrifuge
tube containing plasma sample. After vortexing for 1min, the mix-
ture was centrifuged at 13,000× g for 10min. Then, 850L of the
organic phase (ca. 85% of the upper layer) was transferred into
a clean 1.5-mL microcentrifuge tube and placed in a DNA 120
SpeedVac® (ThermoSavant, Hollbrook, NY, USA). The organic phase
containing 6BT and ISwas vacuumed to dryness at 25 ◦C for 30min.
The sample residue was reconstituted in 85L of water before
analysis.
Matrix effect and recovery
For the matrix effect study, aliquots of 100-L pooled blank
plasma together with 100L of water were ﬁrst extracted using
the protocol described in Section 2.4. Then, 6BT and IS standard
solutions were spiked in the extracted plasma matrix resulting in
6BT concentrations of 9.00, 90.0 and 900ng/mL and an IS concen-
tration of 50.0ng/mL. The peak area ratios of 6BT to IS in these
spike-after-extraction (SAE) standards were compared with those
of the corresponding aqueous standard solutions.
For the recovery study, 6BT plasma calibrators at concentrations
of 9.00, 90.0 and 900ng/mL with an IS concentration of 50.0ng/mL
were analyzed. The peak area ratios of 6BT to IS in the plasma
calibrators were compared with those of the corresponding SAE
standards for calculation of IS normalized recovery of 6BT. The peak
areas of IS in the plasma calibrators were compared with those
of the corresponding SAE standards for the calculation of absolute
recovery of the IS.
Stability
Mouse and human plasma test controls (9.00 and 900ng/mL)
were prepared as described in Section 2.3 except the IS standard
was added prior to the liquid–liquid extraction. All experiments
were run in triplicate and the results were compared with freshly
prepared plasma controls.
For the freeze and thaw stability study, the test controls were
undergone three freeze and thaw cycles. In each cycle, the test con-
trols were frozen for at least 24h at −20 ◦C and thawed at room
temperature without help. The short-term temperature stability
study was carried out by leaving the test controls at the room tem-
perature (23 ◦C) for 4–24h. For the long-term stability, the test
controls were stored at −20 ◦C for 30 days prior to analysis.
Method application
The feasibility of the method developed was tested by a pre-
liminary pharmacokinetics study of 6BT in mice. Pharmacokinetic
parameters of 6BTwere determined usingmale C57BL/6mice from
Charles River Laboratories International (Spencerville, OH, USA).
The mice were randomly housed in a group of ﬁve, with an aver-
age body weight of 24g at the time of treatment. 6BT injection
solution (0.2mg/mL) was prepared in 10% DMSO–PBS (1×) solu-
tion and given intraperitoneally as single bolus injection at a dose
of 1mg/kg.
Mouse blood samples were collected into 1.5-mL centrifuge
tubes by cardiac puncture using heparinized needle and syringe
under isoﬂurane anesthesia at 5, 13, 22, 35, 45, 58, 121 and
237min post-6BT injection. An average of 0.4mL of blood sam-
ple was collected from each mouse. The whole blood was placed
on ice immediately and centrifuged at 8000× g for 15min within
1h of the collections. The harvested plasma samples were frozen
at −20 ◦C until analysis. Mouse plasma from mouse injected
with 10% DMSO–PBS (1×) was used as the predose plasma
sample.
Pharmacokinetic analysis was done by WinNonLin nonlinear
estimation program (Version 5.2) (Pharsight Corp., Mountain View,
CA, USA) using PKmodel 5 (1 compartment 1st order, K10=K01, 1st
order elimination).
Results and discussion
Method development
Mass spectrometric detection
In this work, the optimization of 6BT and 2A6BT (IS) responses
was done using the “auto-tune” function of the MassLynx. Since
6BT and the IS were more easily to form protonated species
than deprotonated species by electrospray ionization, the positive-
electrospray-ionization mode was used for 6BT identiﬁcation and
quantiﬁcation. As shown in Fig. 2A and B (the m/z scan by the ﬁrst
quadrupole), 6BT and the IS produced predominant molecular ions
atm/z 375 for [6BT+H]+ andm/z 390 for [IS+H]+, respectively. These
molecular ions producedwere further dissociated intoproduct ions
by collision with argon gas in the second quadrupole (Fig. 2C and
D). The predominant product ions of [6BT+H]+ and [IS+H]+ were
m/z 243 and m/z 258, respectively. Therefore, the mass transition
pairs m/z 375>243 and m/z 390>258 for 6BT and the IS were
chosen for quantiﬁcation by multiple-reaction-monitoring (MRM)
mode.
The major fragments of 6BT and the IS were proposed by com-
paring the chemical structures of these compounds together with
the m/z differences between the predominant product ions and
shown in Fig. 3.
Chromatographic separation
Since the logD values of 6BT and 2A6BT at pH 3 (i.e., pH
of the mobile phase) are 1.45 and 0.94 as given by SciFinder®,
these analytes are rather hydrophobic than hydrophilic. There-
fore, reverse-phase LC column was used for analytical separation.
In this work, two C18-based columns, Phenomenex Gemini® col-
umn (2.0mm×50mm, 5m particle size with 110Å pore size)
and Waters YMC ODS-AQ® column (2.0mm×50mm, 5m par-
ticle size with 120Å pore size) had been tested. Either column gave
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Fig. 2. The mass spectra of 6BT and the internal standard. The experimental conditions were the same as those described in Section 2.2.
Fig. 3. The proposed major fragments of 6BT and the internal standard.
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Fig. 5. Representative MRM chromatograms of mouse plasma samples. (A) pre-
dosed mouse plasma with IS, (B) the plasma sample collected 5min after
intraperitoneal injection with IS, and (C) the plasma sample collected 13min after
intraperitoneal injection with IS.
a single QC sample at each concentration level, which ranged 3–6%
and 0.6–11% in mouse and human plasma, respectively (Table 3).
The accuracies of the above studieswere −13 to 5% (Table 3), which
were well within the FDA guidelines.
Stability
The stabilities of 6BT inmouse andhumanplasmawere tested at
two concentration levels (9.00 and 900ng/mL) with triplicate mea-
surements, and the results expressedas recoverywere summarized
in Table 4. As seen in Table 4, there was no signiﬁcant loss of 6BT
observed in human plasma under the tested conditionswith recov-
ery of 97–108%. For 6BT mouse plasma samples, they were stable
at room temperature up to 4h and after three freeze (−20 ◦C) and
thaw (room temperature) cycles with recovery of 88–106%. There-
fore, 6BT stock solutions and plasma samples were kept at −20 ◦C
for this work, and the analysis of mouse plasma samples was done
within 4-h timeframe.
Method application
The validated LC–MS/MS method was applied to a preliminary
pharmacokinetic study of 6BT in mice. Mouse plasma samples col-
lected by the procedure described in Section 2.7 were thawed in
room temperature. The mouse plasma samples together with eight
calibrators (i.e., one single-blank, one double-blank and six non-
zero) and two sets of QC at low-,mid- and high-concentrations (i.e.,
9, 90, 900ng/mL) were extracted after adding the IS solution and
analyzed by the validated method. The sample having a concentra-
Fig. 6. Plasma concentration–time proﬁle of 6BT in male C57BL/6 mice after
intraperitoneal injection at dosage of 1mg 6BT/kg mouse.
tion beyond theULOQ (i.e., 1000ng/mL) had been re-run alongwith
the dilution QC (DQC) at the concentration of 1600ng/mL after 1:1
dilution with blank mouse plasma.
Representative mass chromatograms of mouse plasma sam-
ples were shown in Fig. 5, where no sign of interference from
endogenous compound in mouse plasma was observed. The
6BT concentration in mouse plasma after single bolus injec-
tion was illustrated in Fig. 6, which ﬁtted well in a nonlinear
one-compartment ﬁrst-order pharmacokinetic model that has
the following estimated parameters with percent relative stan-
dard deviations of 12–15%: Tmax, 18.9min; Cmax 1086ng/mL; T1/2
13.1min; and AUC, 55,731minng/mL.
Conclusions
An LC–MS/MSmethod for the quantitative determination of 6BT
in mouse and human plasma has been developed and validated.
Analytes in plasma were ﬁrst extracted by ethyl acetate and then
separated by Waters YMC ODS-AQ® column prior to the tandem
mass spectrometric detection. Method validation has been carried
out according the FDA guideline. This method had a linear calibra-
tion range of 3.00–1000ng/mL for 6BT in both mouse and human
plasma, and has been successfully applied to the pharmacokinetic
study of 6BT in mice. It may be useful in therapeutic development
of 6BT and its analogues in human.
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